ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. SPY
4. USO
5. SRRK
6. CGEM
7. DFTX
8. AZN
9. SATL
10. LYNX

Go back to ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

Esperion Therapeutics (ESPR) Misses Q4 EPS by 13c, Revenues Miss

February 23, 2021 4:43 PM EST

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($3.89), $0.13 worse than the analyst estimate of ($3.76). Revenue for the quarter came in at $9.64 million versus the consensus estimate of $12.52 million.

Even though 2020 was an exceptionally challenging year, we made progress in our mission of Lipid... More